No Data
No Data
Atossa Therapeutics: USPTO Grants New Patent Directed To Enteric Oral Formulations Comprising (Z)-endoxifen As Well As Methods Of Treating Subjects With Oral Formulations
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
Atossa Therapeutics Price Target Raised to $7.25/Share From $7.00 by Ascendiant Capital
Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
Express News | Atossa Therapeutics Inc - Intas Pharmaceuticals Files Petition for Post Grant Review Against Co- SEC Filing